Revenue grew 39% year-over-year in H1 2026, driven by strong U.S. and international sales, especially for CellTolerance. Probe sales and system adoption accelerated, with a robust outlook for H2 2026 and a target of adjusted EBITDA breakeven by end-2027.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.